The impressive clinical activity of small-molecule receptor tyrosine kinase inhibitors for
oncogene-addicted subgroups of non-small-cell lung cancer (for example, those driven by …

Checkpoint inhibitor-based immunotherapies that target cytotoxic T lymphocyte antigen 4
(CTLA4) or the programmed cell death 1 (PD1) pathway have achieved impressive success …

Single-cell RNA-sequencing has emerged as a powerful technique for characterizing
cellular heterogeneity, but it is currently impractical on large sample cohorts and cannot be …

Small cell lung cancer (SCLC) is an exceptionally lethal malignancy for which more effective
therapies are urgently needed. Several lines of evidence, from SCLC primary human …

Cancers that appear morphologically similar often have dramatically different clinical
features, respond variably to therapy and have a range of outcomes. Compelling evidence …

Tumors display reprogrammed metabolic activities that promote cancer progression. We
currently possess a limited understanding of the processes governing tumor metabolism in …

Lung cancer is closely associated with chronic inflammation, but the causes of inflammation
and the specific immune mediators have not been fully elucidated. The lung is a mucosal …

Importance Data sets linking comprehensive genomic profiling (CGP) to clinical outcomes
may accelerate precision medicine. Objective To assess whether a database that combines …

An estimated 20% of all patients with cancer will develop brain metastases, with the majority
of brain metastases occurring in those with lung, breast and colorectal cancers, melanoma …

Approximately 30% of human lung cancers acquire mutations in either Keap1 or Nfe2l2,
resulting in the stabilization of Nrf2, the Nfe2l2 gene product, which controls oxidative …